September 27, 2026 · AxonCPT Team · telehealth, adult ADHD, ADHD assessment, clinical practice

How to Run a Telehealth Adult ADHD Evaluation

A telehealth ADHD evaluation for an adult uses the same diagnostic standard as an in-office one: DSM-5-TR criteria, symptoms that began in childhood, impairment in more than one setting, and a reasoned exclusion of other explanations. What changes is the logistics. Over video, you have to confirm the patient’s identity and location, plan ahead for collateral information and objective data, and document more carefully, because a remote Schedule II prescription draws more scrutiny. This guide walks PMHNPs through the whole workup, from the pre-visit checks to the first follow-up.

Nurse practitioner conducting a telehealth adult ADHD evaluation over a laptop video call Photo by Vitaly Gariev on Unsplash

The demand is real. CDC’s National Center for Health Statistics estimated that 15.5 million U.S. adults had a current ADHD diagnosis in 2023, and that about half of adults with ADHD had used telehealth for ADHD-related services [1]. Many of those visits are with PMHNPs. The structure below is built so that a colleague, a payer, or a regulator reading your chart could follow how you reached your diagnosis. Where a standardized measure helps, we show how objective ADHD testing with AxonCPT fits in, but the workflow stands on its own without it.

What to confirm before a telehealth ADHD evaluation

Take care of these before the first video visit:

  • Licensure and location. You need a license in the state where the patient is physically located during the visit. Confirm the location at the start of every visit and record it in the note.
  • Prescribing authority. Check your state’s APRN rules for Schedule II prescribing, including any collaboration or supervision requirements, and your DEA registration for that state. Our guide to PMHNP telehealth stimulant prescribing by state covers the state layer.
  • Federal telemedicine rules. Through December 31, 2026, DEA’s temporary flexibilities allow Schedule II prescribing after an audio-video visit without a prior in-person evaluation, as long as the rule’s conditions are met [2]. What comes after that is unsettled. See DEA special registration for telemedicine, explained.
  • Identity verification. Check a photo ID on camera and record that you did.
  • Consent. Get telehealth consent, and tell the patient up front that an evaluation does not guarantee a diagnosis or a prescription. Saying this early prevents disputes later.
  • Pre-visit forms. Send a self-report screener such as the WHO Adult ADHD Self-Report Scale (ASRS) [3], a medical and psychiatric history form, and a request for informant ratings.

Step 1: The diagnostic interview over video

DSM-5-TR requires the following for adults (age 17 and older) [4]:

  • Five or more symptoms of inattention and/or hyperactivity-impulsivity, lasting at least six months
  • Several symptoms present before age 12
  • Symptoms in two or more settings, such as work, home, or relationships
  • Clear interference with functioning
  • Symptoms not better explained by another mental disorder

A semi-structured interview keeps a video evaluation consistent from patient to patient. The DIVA-5 is a commonly used free option for adults [5]. Over video, ask for concrete examples, such as missed deadlines, driving incidents, job changes, or unpaid bills, rather than just “yes, that’s me.” Specific examples are harder to exaggerate, and they document impairment better.

Step 2: Collateral and childhood history

Establishing childhood onset is where remote evaluations most often come up short. CDC notes that clinicians may ask permission to gather information from family and friends to establish whether symptoms were present before age 12 [6]. Remote options include:

  • A phone or video call with a parent, sibling, or partner, with the patient’s consent
  • An informant rating form sent electronically
  • Old school report cards, teacher comments, or prior evaluations the patient can photograph and upload

If no collateral is available, say so in the note and explain how you weighed that.

Step 3: Differential diagnosis and medical screening

CDC lists anxiety, depression, sleep problems, substance misuse, and learning disabilities as conditions that can mimic or co-occur with adult ADHD [6]. Over video:

  • Screen for mood and anxiety disorders, and ask specifically about bipolar symptoms, because a stimulant can destabilize a manic course.
  • Ask about sleep in detail, including sleep apnea risk and shift work.
  • Take a substance use history. Check the PDMP and document the check.
  • Ask about cardiac history and family history of sudden cardiac death. Ask for a recent blood pressure and heart rate from a home cuff, a pharmacy kiosk, or a primary care record.

Step 4: Validity of the presentation

Stimulants have street value, so symptom validity is part of the clinical standard, not a sign of suspicion toward the patient. A review in Brain Sciences concluded that self-report rating measures are easily simulated by people without ADHD, and that no questionnaire has proved robust enough against false positives [7]. Things that help:

  • Inconsistencies between the self-report, informant report, and the patient’s history
  • Functional evidence that doesn’t fit the reported symptoms
  • Performance-based data. A 2025 meta-analysis in Assessment found that CPTs distinguish credible from noncredible performance with a moderate effect (g = 0.73), and advised that decisions rest on several measures, not one CPT [8]

Step 5: Add an objective attention measure

A continuous performance test (CPT) gives the chart a behavioral, norm-referenced data point that doesn’t depend on recall. It has real limits: a JAACAP meta-analysis in children and adolescents found pooled sensitivity of 0.75 and specificity of 0.71 for CPT total or ADHD scores. The authors concluded CPTs should be used only within a more comprehensive diagnostic process [9]. Treat a CPT as corroborating evidence, never as the deciding factor.

The telehealth question is whether a test taken at home is valid. That depends on how you set up the testing environment and how you interpret the results. We cover it in detail in Remote CPT Testing: Validity and Environment Controls. If you’re comparing remote-capable platforms, our QbCheck pricing guide shows what one remote test costs per patient and how it compares.

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

Step 6: Formulate, document, and decide

Your note should show your reasoning, not just the diagnosis code:

Chart element What to record
Criteria Which DSM-5-TR symptoms are met, with examples
Onset Evidence of symptoms before age 12, and its source
Settings and impairment At least two settings, with concrete consequences
Differential What you considered and why you ruled it in or out
Validity Consistency across sources, plus any performance data
Safety PDMP check, substance use screen, cardiac screen, vitals
Objective data Rating scale scores and CPT results with dates
Plan Medication rationale, target symptoms, and how you will measure response

For payer-ready detail, see ADHD documentation for stimulant prescribing.

How this looks in practice

A typical PMHNP telehealth sequence looks like this:

  1. Before the visit: the patient completes the ASRS and history forms, an informant completes a rating form, and you check the PDMP.
  2. Visit 1 (video, 60–90 minutes as your practice allows): verify identity and location, do the semi-structured interview, take the developmental history, and screen for the differential.
  3. Between visits: you send an AxonCPT link. The patient takes the test in their browser on a laptop or tablet at home, in about 16 minutes, with no app or login. The report is ready as soon as they finish, with five metrics, cohort-matched norms from a 20,000+ reference dataset, and a Q1–Q4 vigilance breakdown. You can see what the report looks like.
  4. Visit 2: review the rating scales, collateral information, and CPT results together. Give the patient feedback, make the diagnostic decision, and document your reasoning.
  5. Follow-up: if you start a stimulant, retest at dose changes and compare results with the baseline alongside the patient’s report, side effects, and vitals.

Frequently asked questions

Can you diagnose adult ADHD entirely over telehealth? Clinically, many clinicians do, using the same DSM-5-TR criteria. Whether you can then prescribe a Schedule II stimulant without an in-person visit depends on federal DEA rules, which are in flux after December 31, 2026, and on your state’s law [2]. Confirm both with counsel.

How long should a telehealth ADHD evaluation take? No federal standard sets the length. A thorough adult workup usually takes more than one contact, covering the interview, collateral information, and testing. In the Done Global case, DOJ cited initial visits “capped at half the length of a typical examination” as part of the scheme [10], so a rushed evaluation is a documentation risk in itself.

Is an at-home CPT valid? Research on home-administered CPTs shows meaningful agreement with lab-based testing [11], with caveats about environment and devices. Standardize the setup and note any problems. See our remote CPT validity guide.

Do I need a CPT to prescribe stimulants? No regulation requires one. It adds objective, repeatable data to a record that otherwise rests largely on self-report.

Start testing your patients with AxonCPT

A telehealth ADHD evaluation holds up when every conclusion traces back to data. AxonCPT gives PMHNPs a fast, home-administered objective measure that fits between video visits and supports your stimulant documentation. Create your free AxonCPT account with 2 free tests every month and no card required, or learn more at axoncpt.com.

References

  1. Staley BS, et al. ADHD Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. MMWR 2024;73(40):890–895.
  2. Drug Enforcement Administration & HHS. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, 90 FR 61301, December 31, 2025.
  3. Kessler RC, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–256.
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.
  5. DIVA Foundation. DIVA-5: Diagnostic Interview for ADHD in Adults.
  6. Centers for Disease Control and Prevention. ADHD in Adults. Reviewed September 1, 2026.
  7. Sadek J. Malingering and Stimulant Medications Abuse, Misuse and Diversion. Brain Sci. 2022;12(8):1004.
  8. Toptas P, et al. Evaluating Continuous Performance Tests as Embedded Measures of Performance Validity in ADHD Assessments: A Systematic Review and Meta-Analysis. Assessment. 2025.
  9. Arrondo G, et al. Systematic Review and Meta-Analysis: Clinical Utility of Continuous Performance Tests for the Identification of ADHD. J Am Acad Child Adolesc Psychiatry. 2024;63(2):154–171.
  10. U.S. Department of Justice, Office of Public Affairs. Founder/CEO and Clinical President of Digital Health Company Sentenced to 72 Months and 24 Months, Respectively, for $90 Million Scheme to Distribute over 37 Million Pills of Adderall. July 7, 2026.
  11. Raz S, et al. Reliability and validity of the online continuous performance test among young adults. Assessment. 2014;21(1):108–118.